ESMO | Poster | Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Authors: Danielle Delombaerde1, Annelies Verbiest2, Laura Tack3, Clara L. Oeste4, Laura Deckx4, Lieselot Croes2, Iege Bassez4, Dries Hens4, Constantijn Franssen5, Vincent Geldhof6, Philip Debruyne3, Johan De Sutter7, Christof Vulsteke1
Download our poster, as presented at ESMO 2024, and get more insights into the methodology used and the results obtained in the multi-center study analyzing EHRs of over 1500 patients.
Background
• Immune checkpoint inhibitors (ICIs) have been associated with cardiovascular (CV) adverse events (AE).
• We aimed to describe the proportion of CV events in a real-world cohort of Belgian cancer patients.
• We included 1571 patients who received at least 1 ICI cycle between March 2017 and August 2022 at 3 Belgian hospitals.
Conclusions
To our knowledge, this is the first study using a dataset enriched with NLP-processed EHRs that describes the frequency and onset time of CV events. The frequency of CV events was higher than reported in clinical trials, but similar to other real-world studies. However, we did observe a later time to onset. Hence, clinicians should note that CV AEs can present in various ways and at any time during or after treatment.
Complete the form above to download the poster and discover the methods used and the results obtained.
Click HERE to visit our Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.
1 Department of Oncology, General Hospital AZ Maria Middelares, Ghent, Belgium and Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
2 Department of Oncology Antwerp University Hospital, Antwerp, Belgium
3 Department of Medical Oncology, General Hospital AZ Groeninge, Kortrijk, Belgium
4 LynxCare, Leuven, Belgium
5 Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium and Cardiovascular Research Group, GENCOR Research Unit, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
6 Department of Oncology, General Hospital AZ Klina and General Hospital AZ Voorkempen, Antwerp, Belgium
7 Department of Cardiology, AZ Maria Middelares, Ghent, Belgium and Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
Background
• Immune checkpoint inhibitors (ICIs) have been associated with cardiovascular (CV) adverse events (AE).
• We aimed to describe the proportion of CV events in a real-world cohort of Belgian cancer patients.
• We included 1571 patients who received at least 1 ICI cycle between March 2017 and August 2022 at 3 Belgian hospitals.
Conclusions
To our knowledge, this is the first study using a dataset enriched with NLP-processed EHRs that describes the frequency and onset time of CV events. The frequency of CV events was higher than reported in clinical trials, but similar to other real-world studies. However, we did observe a later time to onset. Hence, clinicians should note that CV AEs can present in various ways and at any time during or after treatment.
Complete the form above to download the poster and discover the methods used and the results obtained.
Click HERE to visit our Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.
1 Department of Oncology, General Hospital AZ Maria Middelares, Ghent, Belgium and Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
2 Department of Oncology Antwerp University Hospital, Antwerp, Belgium
3 Department of Medical Oncology, General Hospital AZ Groeninge, Kortrijk, Belgium
4 LynxCare, Leuven, Belgium
5 Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium and Cardiovascular Research Group, GENCOR Research Unit, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
6 Department of Oncology, General Hospital AZ Klina and General Hospital AZ Voorkempen, Antwerp, Belgium
7 Department of Cardiology, AZ Maria Middelares, Ghent, Belgium and Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
